CLINICAL CORE

临床核心

基本信息

批准号：
7624797
负责人：
BRUCE L MILLER
金额：
$ 28.07万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-04-01 至 2014-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7624797
关键词：
Accounting Aging Alzheimer&apos s Disease Amyotrophic Lateral Sclerosis Anatomy Basic Science Behavioral Biological California Cells Chinese American Clinical Clinical Data Cognitive Creutzfeldt-Jakob Syndrome Dementia Diagnosis Disease Doctor of Philosophy Early Diagnosis Education Elderly Emotions Enrollment Epidemic Epidemiology Family member Frontotemporal Lobar Degenerations Funding Generations Genetic Genomics Goals Grant HIV Heterogeneity Instruction Intervention Language Latino Linguistics Link Measures Motor Mutation Nerve Degeneration Neurodegenerative Disorders Neurologic Neurologist Pathogenesis Pathology Patient Care Patients Personality Play Prevalence Progressive Supranuclear Palsy Proteomics Recruitment Activity Research Research Personnel Research Subjects Role Sampling San Francisco Scientist Staging Susceptibility Gene Training Training Programs United States Universities Work biological research cohort corticobasal degeneration disorder control executive function improved mild neurocognitive impairment multidisciplinary neuroimaging neuropathology normal aging novel novel strategies oculomotor older patient programs repository research study success tau Proteins

项目摘要

The overarching goal of the Clinical Core is to characterize the behavioral, cognitive, motor, neuroimaging, proteomic and genetic features of ADRC subjects in novel, multidisciplinary ways, and facilitate enrollment of subjects in studies of normal and abnormal aging. The specific aims of the Clinical Core are to 1) Recruit, evaluate, and longitudinally follow cohorts of normal elderly (n=300), patients with mild cognitive impairment (MCI; n=150), mild AD (n=100), frontotemporal lobar degeneration (FTLD; n=75), HIV (n=50), amyotrophic lateral sclerosis (ALS; n=20), corticobasal degeneration and progressive supranuclear palsy (CBD/PSP; n=25), and Creutzfeldt-Jakob disease (CJD; n=20), and members of families with known mutations in genes that predispose them to FTLD; 2) Work with the Education Core to recruit, evaluate, and longitudinally follow Chinese-American (n=100) and Latino (n=50) patients and controls; 3) Provide clinical data and well characterized subjects for research on aging and neurodegenerative disease; and 4) Obtain biological samples for genomic and proteomic research, and contributing novel cohorts, including Chinese-American and FTLD patients, to the National Cell Repository for AD (NCRAD). All subjects will be evaluated using the UDS plus several neurological, cognitive, and personality measures specific to UCSF to better understand the heterogeneity of and overlap between dementias, improve our ability to capture the very earliest signs of neurodegeneration, study the transition from normal aging to MCI, and facilitate interventions. RELEVANCE (See instructions): The prevalence of dementing disorders will soon reach epidemic proportions in the United States. By recruiting and assessing a broad range of patients and elderly controls, the Clinical Core of this ADRC plays a central role in this ADRC's ability to promote the interventional, translational, and biological research in dementias necessary to develop new treatments and optimize patient care.

临床核心的总体目标是表征行为，认知，运动，神经成像， ADRC受试者的蛋白质组学和遗传特征以新颖的多学科方式，并促进入学正常和异常衰老研究的受试者。临床核心的具体目的是1）招募，评估和纵向跟随正常老年人群（n = 300），患有轻度认知障碍的患者（MCI; n = 150），轻度AD（n = 100），额颞叶变性（FTLD； n = 75），HIV（n = 50），肌营养不良侧硬化症（ALS; n = 20），皮质型变性和进行性核上麻痹（CBD/PSP； n = 25）和creutzfeldt-jakob病（CJD; n = 20），以及基因已知突变的家庭成员这使他们容易成为ftld； 2）与教育核心一起招募，评估和纵向遵循中国裔美国人（n = 100）和拉丁裔（n = 50）患者和对照组； 3）提供临床数据和井对衰老和神经退行性疾病的研究的特征受试者； 4）获得生物学基因组和蛋白质组学研究的样本，并贡献新的同类群体，包括中国裔美国人和FTLD患者，到国家细胞存储库AD（NCRAD）。所有受试者将使用 UDS以及UCSF特有的几种神经，认知和人格措施，以更好地理解痴呆症之间的异质性和重叠的异质性，提高了我们捕获最早迹象的能力神经变性，研究从正常衰老到MCI的过渡，并促进干预措施。相关性（请参阅说明）：痴呆症的患病率很快将在美国达到流行比例。经过招募和评估广泛的患者和老年对照组，该ADRC的临床核心是 ADRC促进介入，翻译和生物学研究的能力中的核心作用开发新疗法并优化患者护理所需的痴呆症。